MIRA Pharmaceuticals appoints Brian Daly to Board, David Vorhoff resigns

MIRA PHARMACEUTICALS, INC.

Brian Daly appointed to Board of Directors on October 25, 2023.
Daly named Audit Committee Chair and Compensation Committee member.
David Vorhoff resigned from Board on October 19, 2023, with no disagreements.
Daly brings over 30 years of Wall Street experience; currently Managing Partner at Dalglish Investment Holdings.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Vorhoff

Director

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2023-10-19
Filed: October 25, 2023, 7:59 PM ET

Also, on October 19, 2023, David Vorhoff, resigned from the Board of Directors of the Company.

Appointed

Brian Daly

Director

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2023-10-25
Filed: October 25, 2023, 7:59 PM ET

On October 25, 2023, the Board of Directors (the “Board”) of MIRA Pharmaceuticals, Inc. (the “Company”) unanimously approved the election and appointment of Mr. Brian Daly to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Vorhoff resigned as Director at MIRA PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

Also, on October 19, 2023, David Vorhoff, resigned from the Board of Directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Daly was appointed as Director at MIRA PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

On October 25, 2023, the Board of Directors (the “Board”) of MIRA Pharmaceuticals, Inc. (the “Company”) unanimously approved the election and appointment of Mr. Brian Daly to the Board.

View on SEC.gov

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-038279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.